Related Experiment Video
Updated: Mar 21, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic
Marta García-Queiruga1, Laura María Martínez-López1, María Isabel Martín-Herranz1
1Servicio de Farmacia. Complexo Hospitalario Universitario A Coruña. Spain.. marta.garcia.queiruga@sergas.es.
Insights
This study found no significant link between imatinib treatment adherence and therapeutic response in chronic myeloid leukemia patients. Further investigation is needed for cases of treatment failure.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Imatinib is a tyrosine kinase inhibitor used to treat CML.
- Treatment adherence is crucial for optimal therapeutic outcomes.
Purpose of the Study:
- To evaluate imatinib treatment adherence in CML patients.
- To determine the association between adherence levels and therapeutic response.
Main Methods:
- A study was conducted from October 2013 to March 2014.
- Adherence was measured using the Morisky-Green Questionnaire and medication dispensing records.
- Therapeutic response was assessed based on clinical guidelines; Pearson's Chi-Square Test was used for analysis.
Main Results:
- 31 CML patients were included in the study.
- No statistically significant differences in molecular response were observed between patients with high and intermediate adherence.
- No association was found between the level of adherence and therapeutic response.
Conclusions:
- The study could not establish a definitive link between imatinib adherence and therapeutic response.
- Adherence should be considered in cases of therapeutic failure or suboptimal response.
Objective:
To assess the level of adherence to treatment with imatinib in patients with chronic myeloid leukaemia and its association with therapeutic response.
Materials And Methods:
Study conducted on October, 2013 - March, 2014, including patients diagnosed with Chronic Myeloid Leukaemia on treatment with imatinib in the hospital. Therapeutic adherence was assessed through the standard Morisky-Green Questionnaire and the medication dispensing record. Those patients who did not complete 6 months of treatment and/or did not complete the questionnaire were excluded. Therapeutic response was assessed following clinical guidelines. The descriptive analysis of variables and correlation was conducted through Pearsons's Chi-Square Test.
Results:
The study included 31 patients. When assessing the level of association between response variables and therapeutic adherence: 1. The highest molecular response was reached by 68.4% of those patients with high adherence, and by 75% of those patients with intermediate adherence. 2. Complete molecular response was achieved by 57.9% of patients with high adherence, and by 58.3% of patients with intermediate adherence. No statistically significant differences were found in response variables between patients with high and intermediate therapeutic adherence. No association was observed between level of adherence and therapeutic response.
Conclusions:
We cannot confirm that a different level of therapeutic adherence might have an impact on response to imatinib, though this should be taken into account in cases of therapeutic failure or sub-optimal response.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase